At a Glance
| Feature | Detail |
|---|---|
| What it is | Vendor-made blend of three research peptides in one vial |
| Typical label | GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg (70 mg); compositions vary by vendor |
| Rationale | Collagen and skin remodelling (GHK-Cu) plus soft-tissue repair signalling (BPC-157) and cell migration and angiogenesis (TB-500) |
| Route | Subcutaneous injection |
| Typical practice dose | About 2 mg GHK-Cu per injection (≈0.4 mg BPC-157 + 0.4 mg TB-500), daily or 5 days/week, 6–8 weeks |
| Evidence level | Limited: the combination is untested; components range from limited (BPC-157, TB-500) to emerging (topical GHK-Cu) |
| Regulatory status | No component approved as a medicine by FDA or EMA; all three on FDA’s significant-safety-risk compounding list (GHK-Cu for injection); WADA 2026: prohibited (BPC-157 in S0, TB-500 in S2.3) |
GLOW is the best-known of the pre-mixed peptide blends sold by research-chemical vendors. It started in online communities as a skin-and-healing protocol and became a product: one vial, one injection, three peptides. The appeal is convenience and the name. The problem is that the mixture itself has never been studied, the ratio is fixed by the vendor rather than by any biology, and independent lab testing of blends shows how hard it is to know what is actually in the vial.
My verdict: GLOW is a convenience format for three peptides that each have a thin evidence base. If you understand each component, you understand most of GLOW. What the blend adds is extra uncertainty.
The components
| Component | Labelled amount | What the evidence says | Full article |
|---|---|---|---|
| GHK-Cu | 50 mg | Copper tripeptide; controlled human data for topical skin use, gene-expression and wound data, no trials of injection [3] | GHK-Cu |
| BPC-157 | 10 mg | Gastric pentadecapeptide; mostly rat data; a 2026 systematic review found 3 human studies with 30 participants and very low certainty [2] | BPC-157 |
| TB-500 | 10 mg | Sold as a thymosin beta-4 fragment or analogue; thymosin beta-4 promotes angiogenesis and wound healing in animal models [4] | TB-500 |
The only human data involving two of these together is a retrospective series of 16 knee-pain patients given intra-articular BPC-157, alone or with thymosin beta-4, at one private clinic, without a control group [1]. No study has tested all three, injected subcutaneously, at the GLOW ratio. The broader logic of combining them is discussed in the peptide stacking guide.
Stability and quality concerns
- Composition varies. Vendors sell “GLOW” at 70 mg (50/10/10) and at other ratios such as 25/10/5 mg or 27/5/10 mg; one independent test aggregator lists GLOW vials from about 10 to 70 mg (Peptigrity).
- Independent tests are mixed. An independent testing service lists four GLOW tests: one pass, one fail and two incomplete (Finnrick).
- Copper in a shared vial. GHK-Cu itself is fairly stable in water at pH 4.5–7.4 but degrades under oxidative and alkaline stress [5]. Copper ions can catalyse oxidation of susceptible amino acids in other peptides, histidine being a documented example [6]. No peer-reviewed study has tested whether BPC-157 or TB-500 stays intact when stored with GHK-Cu after reconstitution.
- What “TB-500” means. The name is used both for a short fragment and for full-length thymosin beta-4, and certificates for some blends list the full-length protein. Full-length thymosin beta-4 contains methionine, an oxidation-prone amino acid.
- One purity number for three peptides. Some certificates report a single purity for the whole vial, which can hide one underdosed component.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Skin, hair, general repair (standard) | About 2 mg GHK-Cu per injection (≈0.4 mg BPC-157 + 0.4 mg TB-500 from a 50/10/10 vial; ≈2.8 mg total blend) | SC | Once daily, or 5 days on and 2 off | 6–8 weeks, then 3–4 weeks off | Practice protocol (PeptideMind, r/PeptideGuide, r/PeptideForum) |
| Lower-dose variant | About 1.5 mg GHK-Cu (≈0.3 mg each of BPC-157 and TB-500) | SC | Daily | 6–8 weeks | Anecdotal (glp1forum) |
| Titration | Start at about half the target dose for a week, then increase | SC | Daily | First 1–2 weeks | Anecdotal (r/USPeptides) |
| Separate peptides, for comparison | GHK-Cu 1–2 mg/day; BPC-157 250–500 mcg/day; TB-500 2–5 mg 2×/week | SC | As stated | 4–12 weeks | Practice protocol (see the stacking guide) |
The arithmetic matters. At 2 mg GHK-Cu per day, a 50/10/10 vial delivers about 0.4 mg BPC-157 per day (within the usual range) and about 2.8 mg TB-500 per week (at the low end of usual TB-500 practice, and spread daily rather than given in two larger doses). Because the ratio is fixed, raising the dose of one component raises all three. Many users split the dose or dilute more to reduce the sting.
For injection technique and reconstitution, see the peptide injection guide.
What people report: what works and what doesn’t
Reported to work
- Skin: less redness after acne, smoother texture, less visible cellulite; better hair and eyebrow density; less local joint or hip pain; faster recovery after surgery. These are single reports, usually with other treatments running at the same time (r/Peptides_for_Women, r/USPeptides).
Mixed or unclear
- Daily versus 5-days-a-week dosing, and 6 versus 8 weeks on; no data settle either question.
- Whether the effects come from the copper peptide alone; GHK-Cu on its own is the common comparison.
Reported not to work, or disappointing
- Injection-site pain is the main complaint: a burning or wasp-sting feeling, often delayed and peaking hours later, with red, itchy lumps lasting up to two weeks (user reports; the thread sits in a vendor-run subreddit, so it is not linked here).
- A body-wide rash needing an antihistamine, in one report (r/bpc_157).
What a proper trial would need to show: that the fixed combination improves a measured outcome (skin elasticity, wound healing time, tendon function) more than GHK-Cu alone and more than placebo, with stability data for the mixed vial.
Safety and legal status
Each component’s unknowns carry over, and they add up. BPC-157 and thymosin beta-4 both promote new blood vessel growth and cell migration [4], which is a reason for caution with any current or past cancer. GHK-Cu adds copper; people with Wilson’s disease or other copper disorders should avoid injected copper peptides. With three agents in one injection, a side effect cannot be traced to any one of them.
- United States. None of the components is an approved drug. FDA’s page on bulk substances that may present significant safety risks lists BPC-157, TB-500 and GHK-Cu for injectable use [7].
- EU and Germany. No component is authorised as a medicine; supply for human use is supply of an unauthorised medicinal product.
- Sport. Prohibited at all times: BPC-157 is named in WADA S0, and thymosin beta-4 and its derivatives, including TB-500, in S2.3 [8].
Related Articles
- Peptide Stacking: Combining BPC-157, TB-500 and GHK-Cu
- KLOW Blend: GLOW Plus KPV
- GHK-Cu: The Copper Peptide for Tissue Remodeling
- BPC-157 Overview
- TB-500 Overview
- Peptide Sourcing: Quality and Grey-Market Risks
Frequently asked questions
What is in the GLOW peptide blend?
Most vials are labelled 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 (70 mg total). Other ratios exist, for example 25/10/5 mg or 27/5/10 mg, and independent test listings show GLOW vials from about 10 to 70 mg. Always check the per-peptide amounts on the label rather than assuming a standard formula.
Has the GLOW blend been studied?
No. No human or animal study has tested GHK-Cu, BPC-157 and TB-500 together, let alone pre-mixed in one vial. The only human data for any combination involving these peptides is a 16-patient retrospective knee-pain series using BPC-157 with or without thymosin beta-4.
How much GLOW do people inject?
Commonly reported protocols dose by the GHK-Cu content: about 2 mg GHK-Cu per injection, which with a 50/10/10 vial delivers about 0.4 mg BPC-157 and 0.4 mg TB-500, once daily or 5 days a week for 6–8 weeks, followed by 3–4 weeks off.
Why does GLOW sting?
Users consistently describe a burning or wasp-sting feeling, sometimes peaking hours after injection, with red, itchy lumps that can last up to two weeks. The copper peptide component is usually blamed, and higher dilution or splitting the dose are the common workarounds. No study has examined the cause.
References
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. PMID: 34324435. https://pubmed.ncbi.nlm.nih.gov/34324435/
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PMID: 42885452. https://pubmed.ncbi.nlm.nih.gov/42885452/
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015. PMID: 26236730. https://pubmed.ncbi.nlm.nih.gov/26236730/
- Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. PMID: 15037013. https://pubmed.ncbi.nlm.nih.gov/15037013/
- Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016. PMID: 25384620. https://pubmed.ncbi.nlm.nih.gov/25384620/
- Khossravi M, Borchardt RT. Chemical pathways of peptide degradation: IX. Metal-catalyzed oxidation of histidine in model peptides. Pharm Res. 1998. PMID: 9688066. https://pubmed.ncbi.nlm.nih.gov/9688066/
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current as of 22 April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- World Anti-Doping Agency. The 2026 Prohibited List (S0; S2.3), as published in Tractatenblad 2026, 25. https://zoek.officielebekendmakingen.nl/trb-2026-25.html
Disclaimer: This article is for information and education only and is not a prescription or individual medical advice. GLOW and its components are not approved medicines.
